GZR33 Injection

DRUG4 trials

Sponsors

Gan and Lee Pharmaceuticals, USA, Gan & Lee Pharmaceuticals.

Conditions

Healthy SubjectsType 2 DiabetesType 2 Diabetes (T2DM)

Phase 1

A Study to Evaluate the Safety, Tolerance, PK and PD Parameters of GZR33 and GZR101 in Healthy Male Adult Subjects

CompletedNCT06548932

Gan and Lee Pharmaceuticals, USAHealthy Subjects

Start: 2022-06-30End: 2023-02-24Updated: 2024-08-16

A Clinical Study of GZR33 and GZR101 in Healthy Subjects

CompletedNCT06556641

Gan and Lee Pharmaceuticals, USAHealthy Subjects

Start: 2022-12-17End: 2023-02-03Updated: 2024-08-16

Phase 2

A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection OD

RecruitingNCT06558708

Gan and Lee Pharmaceuticals, USAType 2 Diabetes

Start: 2024-06-28End: 2024-12-31Target: 60Updated: 2024-08-19

Phase 3

Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes

RecruitingNCT07527078

Gan & Lee Pharmaceuticals.Type 2 Diabetes (T2DM)

Start: 2026-04-07End: 2027-04-17Target: 350Updated: 2026-07-01